Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

Por Ahmad S. Alotaibi, Musa Yilmaz, Sanam Loghavi, Courtney DiNardo, Gautam Borthakur, Tapan M. Kadia, Beenu Thakral, Naveen Pemmaraju, Ghayas C. Issa, Marina Konopleva, Nicholas J. Short, Keyur Patel, Guilin Tang, Farhad Ravandi, Naval Daver
Publicado em 2020-10-01

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Por Musa Yilmaz, Hagop Kantarjian, Nicholas J. Short, Patrick Reville, Marina Konopleva, Tapan Kadia, Courtney DiNardo, Gautam Borthakur, Naveen Pemmaraju, Abhishek Maiti, Elias Jabbour, Nitin Jain, Ghayas Issa, Koichi Takahashi, Koji Sasaki, Maro Ohanian, Sherry Pierce, Guillin Tang, Sanam Loghavi, Keyur Patel, Sa A. Wang, Guillermo Garcia-Manero, Michael Andreeff, Farhad Ravandi, Naval Daver
Publicado em 2022-05-01